Core Insights - Merck & Co., Inc. is implementing strategic initiatives to address the impending loss of exclusivity for its key drug, KEYTRUDA, anticipating only a shallow revenue dip as a result [1] Group 1: Strategic Initiatives - The company is focusing on innovation to enhance its product portfolio through the introduction of new products [2] - Merck is expanding its oncology pipeline and exploring new treatment options in cardiovascular and other therapeutic areas [2] - Upcoming product launches include WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX [2] Group 2: Clinical Developments - Ongoing clinical trials for MK-1406, aimed at influenza prevention, are taking place in the Southern Hemisphere [3] - The neoantigen therapy V940 is under development, with a melanoma readout expected in 2028 [3] - MK-3000 is being developed to target patients with diabetic macular edema and neovascular AMD [3] Group 3: Growth Opportunities - Merck is developing over 20 new growth drivers in its human health business, targeting a commercial opportunity of $70 billion [4] - The company aims to double its animal health revenue by mid-2030 through strategic business development [4] Group 4: Company Overview - Merck & Co., Inc. is a leading global biopharmaceutical company focused on discovering, developing, and manufacturing prescription medicines, vaccines, and biologic therapies [5] - The company specializes in human health, particularly in oncology, infectious diseases, and immunology, while also providing animal health products [5]

Core Viewpoint - Wells Fargo has raised its price target for Merck (MRK) to $150, driven by the potential of sacituzumab tirumotecan (sac-TMT) to replace chemotherapy in various cancer treatments, alongside the growth of KEYTRUDA and a robust pipeline of 80 Phase 3 studies [1] Group 1: Stock Performance and Predictions - Merck's stock has gained 23% over the past year and 8% year-to-date, currently trading below its 52-week high of $125.14 [1] - The Street consensus price target for Merck is $127.22, while Wells Fargo's target of $150 suggests significant upside potential [1] - Achieving a $150 price target would imply a market capitalization exceeding $283.4 billion, necessitating positive late-stage data for sac-TMT and sustained growth for KEYTRUDA [1] Group 2: Key Drivers of Stock Performance - Emerging growth portfolio: WINREVAIR, Merck's treatment for pulmonary arterial hypertension, generated $467 million in Q4 2025, reflecting a 133% year-over-year increase [1] - KEYTRUDA's revenue reached $8.337 billion in Q4 2025, up 6% year-over-year, with new FDA approvals expanding its indications [1] - The potential of sac-TMT to displace chemotherapy in multiple cancer types represents a significant commercial opportunity for Merck's oncology franchise [1] Group 3: Strategic Developments - The FDA awarded sac-TMT a Commissioner's National Priority Voucher, indicating strong regulatory support for its development [1] - A strategic financing agreement with Blackstone Life Sciences has been established to partially fund the development of sac-TMT [1]

Core Insights - Merck is transforming its portfolio with the launch of several new products, including WINREVAIR, OHTUVAYRE, CAPVAXIVE Enflonsia, and QLEX, which are expected to advance patient care and have blockbuster potential [2] - The company has identified over $70 billion in commercial opportunities from more than 20 new growth drivers in its Human Health business [2] - Merck's Animal Health business is also set to launch multiple products, with expectations to more than double its revenues by the mid-2030s [3] - The company is confident in its future, supported by a robust early-stage pipeline that aims to yield Phase II and Phase III programs in the coming months and years, contributing to revenue growth and patient impact in the 2030s [3]

Merck & Co (NYSE:MRK) FY Conference Summary Company Overview - **Company**: Merck & Co - **Event**: Sixth Annual Healthcare Conference - **Date**: March 03, 2026 - **Key Speakers**: Caroline Litchfield (CFO), Dr. Dean Li (President of Merck Research Laboratories) Key Points Industry and Company Transformation - Merck is transforming its portfolio with the launch of several new products including WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX, aiming for over 20 new growth drivers in human health [2][3] - The company anticipates a commercial opportunity exceeding $70 billion from these products [2] - The animal health business is expected to double its revenues by the mid-2030s [2] Pipeline and Product Development - Merck has a robust early-stage pipeline with six late-stage pipeline readouts expected in 2026 and 2027 [4] - Key products in the pipeline include: - **sac-TMT** and **I-DXd**: Important for cancer treatment, with ongoing trials [7][17] - **MK-3000**: A new mechanism for treating diabetic macular edema and neovascular AMD, targeting patients who do not respond to existing treatments [10][11] - **Islatravir**: A once-weekly oral treatment for HIV, showing over 90% adherence and efficacy in trials [14] - **SAC-TMT**: Differentiated from existing Trop-2 ADCs, with promising data from trials in lung and breast cancer [15][17] Market Dynamics and Competitive Landscape - Merck is confident in navigating the loss of exclusivity for KEYTRUDA, expecting a shallow revenue dip followed by strong growth [3] - The company is focusing on the oral PCSK9 therapy, which is anticipated to catalyze market growth due to guideline changes [25][26] - Merck's inclisiran is expected to launch in Q1 2027, with strong clinical data supporting its efficacy [30] Future Outlook - Merck aims to diversify its product offerings beyond KEYTRUDA, Gardasil, and Animal Health, focusing on first-in-class and best-in-class innovations [61] - The company is committed to driving growth and delivering returns for shareholders through its evolving product portfolio [61] Other Notable Mentions - **Gardasil**: Expected to maintain stable revenues in 2026, with a focus on the mid-adult segment [57] - **MK-1406**: An antiviral conjugate for influenza, targeting immunocompromised patients, with a significant market opportunity [20] - **Nemtabrutinib**: A competitive entry in the CLL market, with a focus on diversifying oncology offerings [48] Conclusion Merck is positioned for significant growth through its diverse pipeline and strategic product launches, with a strong emphasis on innovation and market adaptation. The company is optimistic about its future, aiming to transform its business model and enhance shareholder value.

Core Viewpoint - Merck & Co., Inc. reported fourth-quarter results that met earnings expectations and slightly exceeded revenue forecasts, leading to a more than 2% increase in share price intraday [1] Group 1: Financial Performance - The company posted adjusted earnings per share of $2.04, aligning with analyst estimates [1] - Revenue increased by 5% year over year to $16.4 billion, surpassing the consensus estimate of $16.18 billion [1] Group 2: Growth Drivers - Growth was primarily driven by strong performance in oncology and animal health, along with contributions from newer products [2] - KEYTRUDA sales rose by 7% to $8.37 billion during the quarter [2] - Animal health revenue increased by 8% to $1.51 billion, supported by robust livestock demand [2] Group 3: Future Outlook - The 2026 outlook disappointed investors, with earnings forecasted at $5.00 to $5.15 per share, below analyst expectations of $5.63 [3] - A one-time charge of approximately $3.65 per share related to the acquisition of Cidara Therapeutics impacted the earnings forecast [3] - Revenue for 2026 is projected at $65.5 billion to $67.0 billion, slightly below the consensus of $67.58 billion [3] Group 4: Full-Year Sales - For the full year 2025, Merck reported worldwide sales of $65.0 billion, representing 1% growth, or 2% growth excluding foreign exchange [4] - KEYTRUDA generated $31.7 billion in annual sales [4] - Newer products WINREVAIR and CAPVAXIVE contributed $1.4 billion and $759 million, respectively [4]

Fourth-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA February 3, 2026 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session 2 Agenda Agenda Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., ...

Core Insights - Merck & Co., Inc. reported financial results for Q4 and full year 2025, highlighting a 5% increase in Q4 sales to $16.4 billion and a 1% increase in full-year sales to $65.0 billion, driven by strong demand for its innovative portfolio, particularly KEYTRUDA and new product launches [3][11][14] Financial Performance - Q4 2025 sales reached $16.4 billion, up from $15.6 billion in Q4 2024, marking a 5% increase [3] - Full-year sales for 2025 were $65.0 billion, compared to $64.2 billion in 2024, reflecting a 1% growth [11] - Non-GAAP EPS for Q4 2025 was $2.04, a 19% increase from $1.72 in Q4 2024, while full-year non-GAAP EPS was $8.98, up 17% from $7.65 in 2024 [30][11] Product Performance - KEYTRUDA sales in Q4 2025 were $8.4 billion, a 7% increase from $7.8 billion in Q4 2024, driven by strong global uptake in oncology [7] - GARDASIL sales declined by 34% in Q4 2025 to $1.0 billion, primarily due to lower demand in China and Japan [7] - Animal Health sales grew by 8% in 2025 to $6.4 billion, supported by higher demand for livestock products [16] Strategic Developments - The company completed the acquisition of Cidara Therapeutics for approximately $9.2 billion, enhancing its portfolio [37] - Merck announced positive late-stage trial results from 18 Phase 3 trials and initiated 21 new Phase 3 studies across various therapeutic areas [33] Regulatory and Pipeline Updates - The FDA approved KEYTRUDA and KEYTRUDA QLEX for the perioperative treatment of muscle-invasive bladder cancer [33] - The company is advancing its pipeline with significant regulatory milestones and ongoing studies in oncology, infectious diseases, and cardiometabolic areas [33][36] Future Outlook - For full-year 2026, Merck anticipates sales between $65.5 billion and $67.0 billion, with a non-GAAP effective tax rate expected between 23.5% and 24.5% [41][45] - Non-GAAP EPS for 2026 is projected to be between $5.00 and $5.15, including a one-time charge related to the acquisition of Cidara [46]

Business Strategy & Pipeline - The company is transforming its portfolio with a focus on innovation, expecting over 20 new launches, most with blockbuster potential[9] - The company is actively pursuing science-driven business development transactions to create value[9] - The company has invested over $60 billion since 2021 in business development[47] Financial Outlook - The commercial opportunity from new growth drivers has increased to over $70 billion, reflecting substantial progress[9] - The mid-2030s revenue opportunity from potential new growth drivers is estimated to be over 2X the consensus 2028 total KEYTRUDA sales, representing approximately $35 billion[49] - Ten key programs represent 70% of the >$70 billion commercial opportunity[51] Key Approvals & Data Readouts in 2025 - Significant approvals were achieved in Oncology, including KEYTRUDA QLEX and KEYTRUDA in earlier-stage cancers[10, 14] - WINREVAIR received a PAH label update (ZENITH) in the Cardiometabolic area[11, 24] - ENFLONSIA was approved for RSV in Infectious Disease[12, 25] Pipeline Development & Milestones - Approximately 80 Phase 3 studies are ongoing[9] - Multiple Phase 3 readouts are anticipated through 2027 across novel mechanisms[59] - Strategic business development is driving an increase in the mid-2030s commercial opportunity[64]

Group 1: Federal Reserve Actions - The Federal Reserve cut the benchmark rate by 0.25 points to approximately 3.9% in late October, marking the second cut of the year to support growth and hiring despite inflation remaining above the 2% target [1] - Two Fed officials indicated that future rate reductions will depend on incoming data rather than a predetermined easing strategy, leading to a market reaction where the dollar strengthened and gold prices fell [2] Group 2: Investment Focus - Investors are increasingly prioritizing dependable cash flow and balance sheet strength, with a focus on high-yield stocks like Merck (MRK) and Duke Energy (DUK) as safer dividend options in a volatile market [3] Group 3: Merck & Company Overview - Merck & Co. has a market capitalization of approximately $252.7 billion and offers a forward annual dividend of $3.24 per share, resulting in a forward yield of 3.09% and a payout ratio of 37.38% [4] - As of December 3, Merck's stock price is $102.81, reflecting a year-to-date increase of 3.2% and a 0.82% rise over the last 52 weeks [5] Group 4: Financial Performance - Merck's latest quarterly report for the period ending September 25 showed total worldwide sales of $17.3 billion, representing a 4% year-over-year increase, or 3% when excluding currency effects [7] - KEYTRUDA was a significant revenue driver with sales of $8.1 billion, up 10% reported and 8% on a constant-currency basis, while WINREVAIR revenue surged by 141% to $360 million [7] - GARDASIL/GARDASIL 9 sales decreased to $1.7 billion, down 24%, while Animal Health sales grew by 9% to $1.6 billion [8] - The company reported GAAP EPS of $2.32 and non-GAAP EPS of $2.58, exceeding the consensus estimate of $2.36 by $0.22, representing a 9.32% upside surprise [8]

Financial Data and Key Metrics Changes - The company anticipates a greater than $5 billion commercial opportunity starting at the end of the decade, escalating into the early 2030s [10] - The influenza season last year saw 1.6 million hospitalizations, indicating a significant unmet medical need [9] Business Line Data and Key Metrics Changes - The CD388 drug shows 76% efficacy in the chosen dose for phase three, outperforming traditional flu vaccines [5][6] - Ohtuvayre, acquired from Verona, is expected to significantly scale up the company's commercial efforts in treating COPD, with excellent feedback from the market [17][18] Market Data and Key Metrics Changes - Approximately 110 million people in the U.S. are expected to be candidates for CD388 treatment, with 85 million being high-risk or immunocompromised individuals [7][9] - The company is seeing positive uptake in the pulmonary arterial hypertension (PAH) market, with WINREVAIR meeting high expectations [28][29] Company Strategy and Development Direction - The company is focusing on expanding its respiratory portfolio and leveraging its commercial engine to maximize the potential of newly acquired products [17][20] - There is a strong emphasis on addressing unmet needs in various therapeutic areas, including COPD and pulmonary hypertension, with plans for phase three trials in the near future [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the significant unmet need in the influenza treatment space and believes CD388 will provide a compelling value proposition [10] - The company is optimistic about the future of its immunology pipeline, with multiple indications expected to show promising results in the coming years [66][67] Other Important Information - The company is preparing for the launch of an oral PCSK9 inhibitor, which is expected to improve access and adherence to cholesterol-lowering therapies [46][47] - The vaccine portfolio, including Gardasil, is expected to see modest growth despite challenges in certain markets [54][55] Q&A Session Summary Question: Insights on the Cidara deal and its growth opportunity - Management highlighted the high unmet medical need for influenza treatment and the strain-agnostic efficacy of CD388, which is expected to protect high-risk populations [5][6][10] Question: Commercial approach for CD388 and payer context - The company plans to include both vaccinated and unvaccinated high-risk individuals in the phase three program, with research indicating a price point of $500 to $600 per dose would be acceptable to payers [12][13] Question: Updates on Ohtuvayre and its market potential - Management expressed confidence in Ohtuvayre's potential, citing excellent feedback from customers and a significant opportunity to scale its commercial efforts [17][18] Question: Future steps for WINREVAIR and phase three trials - The company plans to start phase three trials next year, focusing on the design to meet regulatory expectations and payer requirements [24][25] Question: Expectations for the oral PCSK9 program - Management believes the oral PCSK9 will provide robust LDL lowering and improve access for patients, potentially changing treatment guidelines [46][47] Question: Updates on the vaccine portfolio and Gardasil - The company anticipates modest growth for Gardasil and is optimistic about the launches of new vaccines like CAPVAXIVE [54][58]